Similar articles

• Hormonal replacement therapy--cardiovascular disease.

  Silfverstolpe G, Crona N. Silfverstolpe G, et al. Acta Obstet Gynecol Scand Suppl. 1986;134:93-5. Acta Obstet Gynecol Scand Suppl. 1986. PMID: 3028030 No abstract available.
• [The fetal risk in endocrine treatments].

  Laplane R, Georges-Janet L. Laplane R, et al. Presse Med (1893). 1968 Apr 6;76(17):785-7. Presse Med (1893). 1968. PMID: 4171401 French. No abstract available.
• [Administration of hormones and endocrine modifiers to pregnant women].

  Crosignani PG. Crosignani PG. Minerva Ginecol. 1977 Oct;29(10):739-43. Minerva Ginecol. 1977. PMID: 74053 Italian. No abstract available.
• [Problems of hormone therapy in pregnancy].

  Piccione E. Piccione E. Clin Ter. 1988 Feb 29;124(4):321-4. Clin Ter. 1988. PMID: 2462475 Review. Italian. No abstract available.
• Oral contraceptives and cardiovascular disease (second of two parts).

  Stadel BV. Stadel BV. N Engl J Med. 1981 Sep 17;305(12):672-7. doi: 10.1056/NEJM198109173051205. N Engl J Med. 1981. PMID: 7022211 Review. No abstract available.